alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Drug trials: efficacy and safety

902 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Pharmacotherapy 2000-01 Treatments

    Rivastigmine is a cholinesterase inhibitor (ChEI) with a structural formula different from that of currently available ChEIs.

  2. No response to high-dose muscarinic agonist therapy in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neurology 1988-04 Clinical trials

    Cholinergic deficiency is the most consistent transmitter system abnormality in Alzheimer's disease.

  3. Adverse drug reactions associated with global cognitive impairment in elderly persons

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Annals of internal medicine 1987-08-01 Drug development

    Adverse drug reactions causing cognitive impairment are an important problem in the elderly.

  4. Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. The Lancet regional health. Europe 2026-03-10 Treatments

    Alzheimer's disease (AD) remains the leading cause of dementia in Europe, with limited therapeutic options despite decades of research.

  5. Anti-amyloid therapies and the transformation of Alzheimer's care pathways: early lessons from the frontline

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. The Lancet regional health. Europe 2026-02-12 Treatments

    The introduction of anti-amyloid monoclonal antibodies marks a major shift in Alzheimer's disease (AD) care, moving treatment toward biological modification and reshaping diagnostic and organizational models.

  6. FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now?

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. International journal of molecular sciences 2026-01-15 Treatments

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by decreased amyloid-beta (Aβ) clearance, enhanced Aβ aggregation, an increased risk of amyloid-related imaging abnormalities (ARIA), and blood-brain barrier (BBB) dysfunction.

  7. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of the American Geriatrics Society 2023-04-20 Digital health tools

    Whether initiation of statins could increase survival free of dementia and disability in adults aged ≥75 years is unknown.

  8. ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. The journal of prevention of Alzheimer's disease 2023-01-01 Cognitive tests and assessment

    Nonclinical data indicate that ACU193 can reduce the toxic effects of amyloid β oligomers.

  9. Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. The journal of prevention of Alzheimer's disease 2023-01-01 Treatments

    Aducanumab is the first FDA-approved amyloid-lowering immunotherapy for Alzheimer's disease.

  10. Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Nature communications 2022-12-10 Digital health tools

    Metformin, a diabetes drug with anti-aging cellular responses, has complex actions that may alter dementia onset.

  11. Alzheimer's Disease: Key Insights from Two Decades of Clinical Trial Failures

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Alzheimer's disease : JAD 2022-01-01 Treatments

    Given the acknowledged lack of success in Alzheimer's disease (AD) drug development over the past two decades, the objective of this review was to derive key insights from the myriad failures to inform future drug development.

  12. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. The journal of prevention of Alzheimer's disease 2017-01-01 Treatments

    The amyloid hypothesis has been the dominant framework for Alzheimer's disease (AD) research, including the development of anti-AD therapies.

  13. Long-Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer's Disease Dementia

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Alzheimer s Disease 2015-02-06 Genetics

    Previous trials have shown promising effects of intranasally administered insulin for adults with Alzheimer's disease dementia (AD) or amnestic mild cognitive impairment (MCI).

  14. Intravenous immunoglobulin for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Clinical & Experimental Immunology 2014-12-01 Treatments

    Initial studies suggested that IVIg contained antibodies against monomeric forms of Aβ 5.

  15. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Psychopharmacology 2014-09-18 Clinical trials

    We found no statistically significant differences in UPDRS scores, plasma BDNF levels or H(1)-MRS measures.

  16. British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. British Journal of Dermatology 2012-11-02 Drug development

    The overall objective of the guideline is to provide up‐to‐date, evidence‐based recommendations for the management of bullous pemphigoid (BP).

  17. Memantine for Agitation/Aggression and Psychosis in Moderately Severe to Severe Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. The Journal of Clinical Psychiatry 2008-03-15 Treatments

    Sixty percent of the total patient group had baseline symptoms of agitation/aggression, delusions, or hallucinations on the NPI.

  18. Aromatherapy as a Safe and Effective Treatment for the Management of Agitation in Severe Dementia

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. The Journal of Clinical Psychiatry 2002-07-15 Clinical trials

    Seventy-one patients completed the trial.

  19. The evolving therapeutic landscape of dementia with Lewy bodies

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. The Lancet. Neurology 2025-12 Brain tissue and pathology

    Dementia with Lewy bodies has a complex clinical presentation, with symptoms spanning cognitive, neuropsychiatric, motor, autonomic, and sleep domains.

  20. Causal effect of conventional anti-dementia drugs on economic burden: an orthogonal double/debiased machine learning approach

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. BMC geriatrics 2025-08-25 Costs and economics

    A total of 12,764,487 weighted older adults with ADRD were included, with 34.60% of them using anti-dementia drugs.

  21. Alzheimer's disease drug development pipeline: 2025

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer's & dementia (New York, N. Y.) 2025-06-03 Drug development

    Clinical trials for Alzheimer's disease (AD) must be registered on clinicaltrials.gov.

  22. Drug repurposing for Alzheimer's disease and other neurodegenerative disorders

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Nature communications 2025-02-19 Drug development

    Repurposed drugs provide a rich source of potential therapies for Alzheimer's disease (AD) and other neurodegenerative disorders (NDD).

  23. Metformin in elderly type 2 diabetes mellitus: dose-dependent dementia risk reduction

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Brain : a journal of neurology 2024-04-04 Drug development

    This study aimed to investigate the controversial association between metformin use and diabetes-associated dementia in elderly patients with type 2 diabetes mellitus (T2DM) and evaluate the potential protective effects of metformin, as well as its intensity of use and dose-dependency, against dementia in this population.

  24. How donanemab data address the coverage with evidence development questions

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024-02-07 Treatments

    The Centers for Medicare & Medicaid Services (CMS) established a class-based National Coverage Determination (NCD) for monoclonal antibodies directed against amyloid for Alzheimer's disease (AD) with patient access through Coverage with Evidence Development (CED) based on three questions.

  25. Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. JAMA 2021-10-26 Costs and economics

    This study evaluates whether patients enrolled in trials of aducanumab, EMERGE and ENGAGE, were representative of patients with dementia enrolled in Medicare by estimating the proportions of Medicare beneficiaries with Alzheimer disease (AD) or mild cognitive impairment (MCI) who would have been excluded from these trials.

From across this topic

9 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

Other topics